| Title |
Differential effects of the D1-DA receptor antagonist SCH39166 on positive and negative symptoms of schizophrenia
|
|---|---|
| Published in |
Psychopharmacology, October 1995
|
| DOI | 10.1007/bf02246069 |
| Pubmed ID | |
| Authors |
J. A. Den Boer, H. J. G. M. van Megen, B. R. Slaap, H. G. M. Westenberg, W. W. Fleischhacker, J. W. Louwerens, G. D. Burrows, O. N. Srivastava |
| Abstract |
In the present open study the effects of the D1-dopamine antagonist SCH 39166 on positive and negative symptoms of schizophrenia (DSM-IIIR) were investigated. SCH 39166 was given orally according to a fixed dosage schedule (day 1: 25 mg b.i.d; day 4: 50 mg b.i.d.; day 7: 100 mg b.i.d.; day 18: 200 mg b.i.d.; day 21: 225 mg b.i.d.). Seven patients completed 2 weeks, and five patients completed the study. The reason for premature withdrawal was lack of efficacy or refusal to take SCH 39166. In none of the patients a reduction of the BPRS or CGI score was found. As measured with the PANSS, a significant reduction was observed in the score of the negative subscale, whereas the positive symptoms scale and general psychopathology score remained unaffected. Akathisia, rigidity and hypokinesia were reported occasionally, although only mild in severity. The results of the present study do not support the hypothesis that D1-dopamine antagonists are clinically effective antipsychotics in schizophrenia, considering the fact that SCH 39166 had no effect on positive symptoms. The present study provides circumstantial evidence for an effect of SCH 39166 on negative symptoms. |
Mendeley readers
The data shown below were compiled from readership statistics for 26 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 26 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 6 | 23% |
| Student > Ph. D. Student | 4 | 15% |
| Student > Doctoral Student | 3 | 12% |
| Student > Bachelor | 3 | 12% |
| Student > Master | 3 | 12% |
| Other | 3 | 12% |
| Unknown | 4 | 15% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 7 | 27% |
| Neuroscience | 4 | 15% |
| Medicine and Dentistry | 4 | 15% |
| Agricultural and Biological Sciences | 3 | 12% |
| Nursing and Health Professions | 2 | 8% |
| Other | 0 | 0% |
| Unknown | 6 | 23% |
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 April 2022.
All research outputs
#3,408,355
of 23,515,383 outputs
Outputs from Psychopharmacology
#850
of 5,408 outputs
Outputs of similar age
#1,471
of 24,494 outputs
Outputs of similar age from Psychopharmacology
#1
of 39 outputs
Altmetric has tracked 23,515,383 research outputs across all sources so far. Compared to these this one has done well and is in the 84th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 5,408 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.8. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 24,494 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 89% of its contemporaries.
We're also able to compare this research output to 39 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 89% of its contemporaries.